These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 18240145

  • 21. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
    Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK.
    Int J Cancer; 2007 Jan 01; 120(1):160-9. PubMed ID: 17013895
    [Abstract] [Full Text] [Related]

  • 22. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
    Liu QJ, Xu XH, Shang DH, Tian Y, Lü WC, Zhang YH.
    Chin Med J (Engl); 2010 Feb 05; 123(3):356-60. PubMed ID: 20193259
    [Abstract] [Full Text] [Related]

  • 23. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 2006 Jul 01; 12(13):4072-9. PubMed ID: 16818707
    [Abstract] [Full Text] [Related]

  • 24. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.
    Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Habuchi T.
    Carcinogenesis; 2011 Nov 01; 32(11):1589-96. PubMed ID: 21828059
    [Abstract] [Full Text] [Related]

  • 25. A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
    Dahmani A, de Plater L, Guyader C, Fontaine JJ, Berniard A, Assayag F, Beuzeboc P, Marangoni E, Némati F, Poupon MF, Pasik C, Oudard S, Decaudin D.
    Anticancer Drugs; 2010 Nov 01; 21(10):927-31. PubMed ID: 20827173
    [Abstract] [Full Text] [Related]

  • 26. Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo.
    Gonzalez-Moreno O, Segura V, Serrano D, Nguewa P, de las Rivas J, Calvo A.
    Int J Cancer; 2007 Sep 15; 121(6):1197-204. PubMed ID: 17520673
    [Abstract] [Full Text] [Related]

  • 27. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
    Crea F, Duhagon Serrat MA, Hurt EM, Thomas SB, Danesi R, Farrar WL.
    Int J Cancer; 2011 Apr 15; 128(8):1946-54. PubMed ID: 20568112
    [Abstract] [Full Text] [Related]

  • 28. Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.
    Cardillo I, Spugnini EP, Galluzzo P, Contestabile M, Dell'Anna ML, Picardo M, Crispi S, Calogero RA, Piccolo MT, Arigoni M, Cantarella D, Boccellino M, Quagliuolo L, Ferretti G, Carlini P, Felici A, Boccardo F, Cognetti F, Baldi A.
    Future Oncol; 2013 Sep 15; 9(9):1375-88. PubMed ID: 23980684
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition.
    Liu X, Gao R, Dong Y, Gao L, Zhao Y, Zhao L, Zhao X, Zhang H.
    BMC Cancer; 2010 Aug 10; 10():418. PubMed ID: 20698994
    [Abstract] [Full Text] [Related]

  • 32. Phenoxodiol inhibits growth of metastatic prostate cancer cells.
    Aguero MF, Venero M, Brown DM, Smulson ME, Espinoza LA.
    Prostate; 2010 Aug 10; 70(11):1211-21. PubMed ID: 20564423
    [Abstract] [Full Text] [Related]

  • 33. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
    Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP.
    Cancer Res; 2004 Oct 15; 64(20):7426-31. PubMed ID: 15492266
    [Abstract] [Full Text] [Related]

  • 34. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.
    Fung AS, Wu L, Tannock IF.
    Clin Cancer Res; 2009 Sep 01; 15(17):5389-95. PubMed ID: 19706800
    [Abstract] [Full Text] [Related]

  • 35. Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells.
    Mori A, Lehmann S, O'Kelly J, Kumagai T, Desmond JC, Pervan M, McBride WH, Kizaki M, Koeffler HP.
    Cancer Res; 2006 Mar 15; 66(6):3222-9. PubMed ID: 16540674
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T, Nakamura K, Araki H, Kusaka M, Yamaoka M.
    Cancer Res; 2003 Sep 01; 63(17):5622-8. PubMed ID: 14500404
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer.
    Koike H, Ito K, Takezawa Y, Oyama T, Yamanaka H, Suzuki K.
    Br J Cancer; 2005 Apr 25; 92(8):1538-44. PubMed ID: 15846301
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.